Anavex Life Sciences Corp.
AVXL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $787,209 | $729,933 | $910,816 | $477,131 |
| - Cash | $101,164 | $115,771 | $120,775 | $132,187 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $686,045 | $614,162 | $790,041 | $344,944 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$13,370 | $1,125 | -$11,466 | -$34,019 |
| % Margin | – | – | – | – |
| Net Income | -$13,243 | -$11,196 | -$12,111 | -$11,620 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.16 | -0.13 | -0.14 | -0.14 |
| % Growth | -23.1% | 7.1% | 0% | – |
| Operating Cash Flow | -$12,464 | -$5,856 | -$12,120 | -$6,658 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$12,464 | -$5,856 | -$12,120 | -$6,658 |